Pain Management News

A Brooklyn-based biotech firm has announced successful completion of the first phase of a preclinical study conducted with the Walter Reed Army Institute of Research involving a proprietary hemostatic hydrogel to treat traumatic brain injury.

A clinical-stage neuroscience-focused biopharmaceutical company has received new international patents related to an investigational neuroactive pherine nasal spray to potentially treat individuals with migraine.

No significant differences were found in clinical outcomes or recovery time in college athletes who returned to play following concussion compared with those immediately removed, according to research from Neurosurgical Focus.

A South Korean biomedical company has announced positive 1-year assessment data from a phase 1/2a clinical trial of a human embryonic stem cell-derived midbrain dopaminergic progenitor for Parkinson’s disease.

Concussions suffered in hockey led to substantial missed playing time, while their physical effects require leagues of all ages to bolster rules, utilize protective equipment and implement high-quality injury protocols to address the issue.

Although there are no current reliable tests and few treatments for chronic inflammatory demyelinating polyneuropathy, which affects about 40,000 individuals in the U.S., recent FDA approvals have made treatments a possibility.

SAN DIEGO — Contraceptive use did not significantly increase risk of vascular events overall for women who experience migraines, although those who experience migraine with aura had an increased risk, data show.

Published results showed an investigational head and neck cooling device reduced symptom severity for adolescent athletes with a sports-related concussion compared with standard post-concussion care alone.

NeuroSense Therapeutics Ltd. has reported positive results from the 12-month data analysis of a phase 2b study evaluating a novel extended-release oral formulation combination therapy in patients with amyotrophic lateral sclerosis.

DENVER - Cenobamate was effective in treating focal seizures administered as a whole tablet, crushed tablet or by nasogastric tube, Vijay Vashi, PhD, in this Healio video from the American Academy of Neurology annual meeting.